Lexi Ventures
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Lexi Ventures.
Key people at Lexi Ventures.
Key people at Lexi Ventures.
Lexi Ventures is a US-based seed-stage venture capital firm specializing in gene technology, focusing on startups that work with DNA, RNA, proteins, cells, and -omics technologies. Their mission is to invest in foundational gene tech innovations that have the potential to transform multiple sectors, including health (therapeutics, diagnostics, vaccines), consumer happiness, food and agriculture, veterinary, and industrial materials/chemicals. Lexi Ventures aims to support founders by providing tailored assistance while moving quickly and minimizing unnecessary interference. They typically invest between $50,000 and $500,000 in early-stage companies that have at least a prototype or early revenue[1][2][4].
Founded with a focus on gene tech, Lexi Ventures is led by General Partner Jonah Probell, who has expertise in gene technologies involving DNA, RNA, proteins, and cells. The firm concentrates on the next wave of technological growth centered on genomics, inspired by the recognition of genomics as a transformative field by leading technologists such as Steve Jobs and Sam Altman. Lexi Ventures co-invests alongside other funds specializing in health, climate, and deep tech to leverage complementary expertise and broaden impact. Since its inception, the firm has steadily invested in about 10 gene tech seed-stage startups annually, placing it among the top 20 VC funds active in this niche alongside major players like Andreessen Horowitz and Y Combinator[1][2].
Lexi Ventures is riding the wave of gene technology as the next major technological revolution, analogous to how computers transformed electronics. The timing is critical as advances in genomics, synthetic biology, and related fields are unlocking new capabilities in health, agriculture, and industrial applications. Market forces such as increased computational power, AI integration, and growing demand for precision medicine and sustainable solutions favor gene tech innovation. By focusing on foundational gene tech startups, Lexi Ventures helps seed the ecosystem that will drive breakthroughs in diagnostics, therapeutics, and beyond, influencing the broader biotech and deep tech landscapes[2][4].
Looking ahead, Lexi Ventures is poised to continue its leadership in early-stage gene tech investing, likely expanding its portfolio as gene editing, synthetic biology, and multi-omics technologies mature. Trends such as AI-assisted gene editing, personalized medicine, and sustainable bio-manufacturing will shape their investment focus. Their influence is expected to grow as gene tech startups they back become key players in transforming healthcare, agriculture, and industrial sectors. Lexi Ventures’ founder-friendly, specialized approach positions it well to capitalize on and help steer the next decade’s gene tech revolution[2][4].
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 1, 2025 | Ria Health | $7.0M Series B | — | SOSV, SV Health Investors |
| Jan 1, 2025 | Delve | $3.0M Seed | — | Y Combinator |
| Sep 1, 2024 | Syntra | $500K Seed | — | Bascom Ventures, Aniq Kassam, Hoxton Ventures, Y Combinator, Charlie Songhurst, Othman Laraki, Todd Corenson |
| Mar 1, 2024 | KAIKAKU | $2.0M Seed | — | Altair Capital Management, Alumni Ventures, Brighter Capital, Episode 1 Ventures, Jenny Fielding, FAST — by GETTYLAB, Felix Capital, Pareto Holdings, Playfair Capital, Point Nine Capital, Preston-Werner Ventures, SmartStart Fund, Workday Ventures, Y Combinator, Christian Bach, Fredrik Björk, Koen Bok, Ran Makavy, Victor Jacobsson, Will Martin |
| Feb 1, 2024 | Delve | $500K Seed | — | Y Combinator |
